Form 4: Day One Biopharmaceuticals Acquired by Servier

Director Garry A. Nicholson reports the cancellation of equity holdings following the acquisition of Day One Biopharmaceuticals by Servier Pharmaceuticals.

Summary

• Day One Biopharmaceuticals, Inc. (DAWN) was acquired by Servier Pharmaceuticals LLC on April 23, 2026.
• Under the merger agreement, all outstanding common stock was converted into the right to receive $21.50 per share in cash.
• Reporting person Garry A. Nicholson held various stock options and restricted stock units (RSUs) that were fully vested immediately prior to the merger.
• All derivative securities held by the reporting person were canceled and converted into the right to receive cash payments based on the $21.50 merger consideration, minus exercise prices and applicable taxes.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the completion of a previously announced merger.

Positives

• Shareholders received a cash consideration of $21.50 per share upon the closing of the merger.
• All unvested stock options and RSUs held by the reporting person were accelerated to full vesting prior to the merger effective time.

Negatives

• The company has ceased to be an independent publicly traded entity as it is now a wholly owned subsidiary of Servier Pharmaceuticals.

Risks

• The company is no longer a publicly traded entity, eliminating future investment opportunities in the stock.

Future Outlook

The company is now a wholly owned subsidiary of Servier Pharmaceuticals; no further public guidance or forward-looking statements are provided.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large pharmaceutical companies acquiring specialized biotech firms to bolster their oncology and rare disease pipelines.

Comparison to Industry Standards

• The $21.50 cash-out price represents the final valuation for public shareholders following the completion of the merger agreement.

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Employees and directors see their equity awards settled in cash.

Next Steps

• Delisting of DAWN common stock from public exchanges.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, Merger, Acquisition, Servier Pharmaceuticals, Form 4, Insider Transaction